Low-sodium diet and salt tablets to see if eczema improves

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 interventional trial investigates whether reducing dietary sodium can improve eczema severity and reduce skin sodium levels in adults with atopic dermatitis. Participants will follow a 24-week low-sodium diet and then enter a randomized cross-over period where they receive sodium chloride tablets or placebo for 5 weeks, with a washout in between. The study uses non-invasive sodium MRI and dietary/clinical assessments to explore the relationship between skin sodium storage and eczema activity. Primary outcomes focus on changes in eczema severity, while secondary analyses examine dietary adherence, urinary biomarkers, and skin sodium concentration. The trial will enroll about 40 participants at UCSF-affiliated sites, including 30 with moderate-severe atopic dermatitis and 10 healthy controls.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants ages 18 years
* Willing and able to undergo non-contrast MRI.

Exclusion Criteria:

* Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants)
* A cardiac event in the past 6 months
* Impaired function of the liver or kidney (glomerular filtration rate \<60 mL/min)
* Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors)
* Antibiotic or immunomodulatory medications within the last month
* Contraindications to sodium tablets

(Topical medications used exclusively on the head/neck or hands/feet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)

Where it's running

• San Francisco VA Medical Center
  San Francisco, California, United States Recruiting
• UCSF Mt Zion Campus
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Katrina Abuabara, MD — University of California, San Francisco
• Study coordinator: Alicia Hamblin, BS
• Email: Alicia.Hamblin@ucsf.edu
• Phone: 925-549-7889

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital mindfulness app for teens with eczema

  Teens with moderate to severe eczema try a digital mindfulness app to see if it helps control symptoms and improve quality of life.

  Recruiting at 2 sites Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT07746427

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Soquelitinib for adults with moderate to severe atopic dermatitis

  This 12-week test gives adults with moderate to severe atopic dermatitis daily soquelitinib or a placebo to see if their skin and itch improve and to track side effects.

  Recruiting Phase 2 Corvus Pharmaceuticals, Inc. · South San Francisco, California · NCT07441395

• GX-03 topical treatment for adults with moderate to severe eczema

  This study will test whether applying GX-03, a topical emollient, twice daily for 8 weeks reduces eczema severity and itch in adults with moderate to severe atopic dermatitis compared with a petrolatum-based vehicle.

  Recruiting Phase 2/3 Turn Therapeutics · Irving, Texas · NCT07355075

• Non-Invasive Skin Fluid Biomarkers in Babies with and without Eczema

  This study tests whether a tiny, painless device can safely collect skin interstitial fluid from babies to see if eczema changes immune signals compared with healthy babies.

  Recruiting King's College London · London · NCT07228962

• IMG-007 for adults with moderate-to-severe atopic dermatitis.

  This study will test if different doses of IMG-007 reduce skin inflammation and itching in adults with moderate-to-severe atopic dermatitis compared with a placebo.

  Recruiting at 23 sites Phase 2 Inmagene LLC · Lancaster, California and 29 other locations · NCT07037901

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.